Sight Sciences, Inc. (NASDAQ:SGHT) Stock Holdings Boosted by D. E. Shaw & Co. Inc.

D. E. Shaw & Co. Inc. boosted its position in Sight Sciences, Inc. (NASDAQ:SGHT - Free Report) by 27.6% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 410,325 shares of the company's stock after buying an additional 88,738 shares during the quarter. D. E. Shaw & Co. Inc. owned 0.81% of Sight Sciences worth $1,494,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. JPMorgan Chase & Co. increased its position in shares of Sight Sciences by 335.3% during the third quarter. JPMorgan Chase & Co. now owns 69,660 shares of the company's stock worth $439,000 after acquiring an additional 53,658 shares during the last quarter. Arkadios Wealth Advisors acquired a new position in shares of Sight Sciences in the 4th quarter valued at approximately $47,000. SG Americas Securities LLC raised its position in shares of Sight Sciences by 47.6% in the 4th quarter. SG Americas Securities LLC now owns 17,622 shares of the company's stock valued at $64,000 after purchasing an additional 5,681 shares in the last quarter. Stoneridge Investment Partners LLC purchased a new position in shares of Sight Sciences during the 4th quarter valued at approximately $55,000. Finally, Charles Schwab Investment Management Inc. grew its position in shares of Sight Sciences by 4.4% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 268,250 shares of the company's stock worth $976,000 after buying an additional 11,259 shares in the last quarter. 55.51% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research firms have commented on SGHT. Citigroup reiterated a "neutral" rating and set a $3.60 price objective (up from $3.20) on shares of Sight Sciences in a research note on Thursday, May 22nd. Lake Street Capital increased their price target on shares of Sight Sciences from $2.50 to $3.00 and gave the stock a "hold" rating in a research report on Friday, May 9th. Needham & Company LLC reiterated a "hold" rating on shares of Sight Sciences in a research note on Wednesday, April 9th. Piper Sandler cut their price objective on Sight Sciences from $5.50 to $3.50 and set a "neutral" rating on the stock in a research note on Thursday, March 6th. Finally, Stifel Nicolaus decreased their target price on Sight Sciences from $5.00 to $4.00 and set a "buy" rating for the company in a research report on Thursday, March 6th. Five analysts have rated the stock with a hold rating and two have given a buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Hold" and an average target price of $4.02.

Insider Activity

In related news, EVP Manohar K. Raheja acquired 10,000 shares of the business's stock in a transaction that occurred on Wednesday, March 12th. The shares were acquired at an average cost of $2.73 per share, for a total transaction of $27,300.00. Following the completion of the purchase, the executive vice president now directly owns 145,000 shares in the company, valued at $395,850. This trade represents a 7.41% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO Paul Badawi sold 24,174 shares of the company's stock in a transaction dated Tuesday, April 1st. The stock was sold at an average price of $2.30, for a total transaction of $55,600.20. Following the completion of the sale, the chief executive officer now directly owns 6,010,580 shares of the company's stock, valued at $13,824,334. The trade was a 0.40% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 35,196 shares of company stock valued at $81,001. Insiders own 30.90% of the company's stock.

Sight Sciences Stock Performance

SGHT stock traded down $0.05 during midday trading on Wednesday, reaching $3.39. The company had a trading volume of 17,590 shares, compared to its average volume of 213,936. The firm has a market capitalization of $175.25 million, a PE ratio of -3.32 and a beta of 2.41. The stock has a 50 day moving average price of $2.84 and a 200 day moving average price of $3.09. Sight Sciences, Inc. has a fifty-two week low of $2.03 and a fifty-two week high of $8.45. The company has a quick ratio of 9.74, a current ratio of 10.18 and a debt-to-equity ratio of 0.36.

Sight Sciences (NASDAQ:SGHT - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.29) by $0.01. Sight Sciences had a negative return on equity of 47.28% and a negative net margin of 63.30%. The business had revenue of $17.51 million for the quarter, compared to the consensus estimate of $16.51 million. Analysts anticipate that Sight Sciences, Inc. will post -0.99 earnings per share for the current year.

Sight Sciences Company Profile

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.